174 related articles for article (PubMed ID: 32398112)
21. Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis.
Zhong C; Cheng X; Jia B; Xiong P; Lu J; Zhang P; Liu X; Chen Y
Medicine (Baltimore); 2020 Nov; 99(47):e23038. PubMed ID: 33217804
[TBL] [Abstract][Full Text] [Related]
22. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
23. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Kruis W; Jonaitis L; Pokrotnieks J; Mikhailova TL; Horynski M; Bátovský M; Lozynsky YS; Zakharash Y; Rácz I; Kull K; Vcev A; Faszczyk M; Dilger K; Greinwald R; Mueller R;
Aliment Pharmacol Ther; 2011 Feb; 33(3):313-22. PubMed ID: 21138455
[TBL] [Abstract][Full Text] [Related]
24. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
Pokrotnieks J; Marlicz K; Paradowski L; Margus B; Zaborowski P; Greinwald R
Aliment Pharmacol Ther; 2000 Sep; 14(9):1191-8. PubMed ID: 10971236
[TBL] [Abstract][Full Text] [Related]
26. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
[TBL] [Abstract][Full Text] [Related]
27. Ginseng-Containing Sijunzi Decoction Ameliorates Ulcerative Colitis by Orchestrating Gut Homeostasis in Microbial Modulation and Intestinal Barrier Integrity.
Wu Y; Zheng Y; Wang X; Tang P; Guo W; Ma H; Zhang A; Li D; Xie Y; Wang CZ; Yao H; Wan JY; Yuan CS
Am J Chin Med; 2023; 51(3):677-699. PubMed ID: 36883990
[TBL] [Abstract][Full Text] [Related]
28. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
29. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
Tang T; Targan SR; Li ZS; Xu C; Byers VS; Sandborn WJ
Aliment Pharmacol Ther; 2011 Jan; 33(2):194-202. PubMed ID: 21114791
[TBL] [Abstract][Full Text] [Related]
30. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
Gionchetti P; Ardizzone S; Benvenuti ME; Bianchi Porro G; Biasco G; Cesari P; D'albasio G; De Franchis R; Monteleone G; Pallone F; Ranzi T; Trallori G; Valpiani D; Vecchi M; Campieri M
Aliment Pharmacol Ther; 1999 Mar; 13(3):381-8. PubMed ID: 10102972
[TBL] [Abstract][Full Text] [Related]
31. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.
Marteau P; Crand J; Foucault M; Rambaud JC
Gut; 1998 Feb; 42(2):195-9. PubMed ID: 9536943
[TBL] [Abstract][Full Text] [Related]
32. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
33. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
34. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Watanabe M; Hanai H; Nishino H; Yokoyama T; Terada T; Suzuki Y
Inflamm Bowel Dis; 2013 Jul; 19(8):1681-90. PubMed ID: 23624890
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
36. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis.
Fiorino G; Sturniolo GC; Bossa F; Cassinotti A; di Sabatino A; Giuffrida P; Danese S
Cells; 2019 May; 8(6):. PubMed ID: 31151306
[TBL] [Abstract][Full Text] [Related]
37. Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Dignass A; Stremmel W; Horyński M; Poyda O; Armerding P; Fellermann K; Langhorst J; Kuehbacher T; Uebel P; Stein J; Novacek G; Avalueva E; Oliinyk O; Hasselblatt P; Dorofeyev A; Heinemann H; Mueller R; Greinwald R; Reinisch W;
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):810-820.e7. PubMed ID: 37806372
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
[TBL] [Abstract][Full Text] [Related]
39. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
Hawkey CJ; Dube LM; Rountree LV; Linnen PJ; Lancaster JF
Gastroenterology; 1997 Mar; 112(3):718-24. PubMed ID: 9041232
[TBL] [Abstract][Full Text] [Related]
40. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
